Literature DB >> 417751

Radiotherapy in the treatment of Hodgkin's disease.

A R Timothy, S B Sutcliffe, A G Stansfeld, P F Wrigley, A E Jones.   

Abstract

Eighty-seven untreated patients with localised Hodgkin's disease seen from 1969 to 1975 were treated by megavoltage radiotherapy. All were followed for at least 33 months. Thirty-three patients were staged clinically and 54 underwent more extensive investigation by lapaortomy and splenectomy. The projected five-year disease-free survival figures for patients staged surgically were 100% for the 17 with stage IA disease, 70% for the 19 with stage IIA disease, and 73% for the 15 with stage IIIA disease. These results were consistently better than those obtained in clinically staged patients. Five patients died, one of them without evidence of Hodgkin's disease. As irradiation seems to produce excellent disease-free survival in most patients who are staged accurately at diagnosis, caution should be exercised in the routine use of adjuvant chemotherapy until the full risks of such treatment are clear. Combined modality therapy may be appropriate for patients with unfavourable features at presentation.

Entities:  

Mesh:

Year:  1978        PMID: 417751      PMCID: PMC1604593          DOI: 10.1136/bmj.1.6122.1246

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  The radical radiotherapy of regionally localized Hodgkin's disease.

Authors:  H S KAPLAN
Journal:  Radiology       Date:  1962-04       Impact factor: 11.105

Review 2.  A decade of combination chemotherapy of advanced Hodgkin's disease.

Authors:  V T DeVita; G P Canellos; J H Moxley
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

3.  Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy.

Authors:  J C Arseneau; R W Sponzo; D L Levin; L E Schnipper; H Bonner; R C Young; G P Canellos; R E Johnson; V T DeVita
Journal:  N Engl J Med       Date:  1972-11-30       Impact factor: 91.245

4.  The management of stages I, II, and III Hodgkin's disease with combined radiotherapy and chemotherapy.

Authors:  S A Rosenberg; H S Kaplan
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

5.  The value of laparotomy and splenectomy in the staging of Hodgkin's disease.

Authors:  E Glatstein; J M Guernsey; S A Rosenberg; H S Kaplan
Journal:  Cancer       Date:  1969-10       Impact factor: 6.860

6.  Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease.

Authors:  H S Kaplan
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

7.  Intensive investigation in management of Hodgkin's disease.

Authors:  S B Sutcliffe; P F Wrigley; J F Smyth; J A Webb; A K Tucker; M E Beard; M Irving; A G Stansfeld; J S Malpas; D Crowther; J M Whitehouse
Journal:  Br Med J       Date:  1976-12-04

8.  Second malignancies complicating Hodgkin's disease in remission.

Authors:  G P Canellos; J C Arseneau; V T DeVita; J Whang-Peng; R E Johnson
Journal:  Lancet       Date:  1975-04-26       Impact factor: 79.321

9.  MVPP chemotherapy regimen for advanced Hodgkin's disease.

Authors:  S B Sutcliffe; P F Wrigley; J Peto; T A Lister; A G Stansfeld; J M Whitehouse; D Crowther; J S Malpas
Journal:  Br Med J       Date:  1978-03-18
  9 in total
  7 in total

1.  Cancer chemotherapy.

Authors:  R J Wrighton
Journal:  J R Soc Med       Date:  1979-01       Impact factor: 5.344

2.  Hodgkin's disease in adults: the challenge.

Authors:  T A Lister
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

3.  [Treatment results of Hodgkin's disease, stages I and II (author's transl)].

Authors:  W Gassmann; H Pralle; H Löffler; M Gluth-Stender
Journal:  Klin Wochenschr       Date:  1981-05-15

4.  Thyroid function in survivors of cancer.

Authors:  S S Abusrewil; M G Mott; A Oakhill; J Bullimore; G Newman; D C Savage
Journal:  Arch Dis Child       Date:  1989-05       Impact factor: 3.791

5.  Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital.

Authors:  T S Ganesan; P F Wrigley; P A Murray; A G Stansfeld; A J d'Ardenne; S Arnott; A Jones; W S Shand; J S Malpas; T A Lister
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

6.  Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.

Authors:  P J Dady; T J McElwain; D E Austin; A Barrett; M J Peckham
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

7.  A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group.

Authors:  H Anderson; D P Deakin; J Wagstaff; J M Jones; I D Todd; P M Wilkinson; R D James; W P Steward; G Blackledge; J H Scarffe
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.